Consists of domperidone, naproxen
What is Domperidone?
Domperidone is a medicine that increases the movements or contractions of the stomach and bowel. Domperidone is also used to treat nausea and vomiting caused by other drugs used to treat Parkinson's Disease.
Domperidone is to be given only by or under the immediate supervision of your doctor.
Domperidone indications
Dyspeptic symptom complex often associated with delayed gastric emptying, gastroesophageal reflux disease (GERD) or esophagitis: Epigastric sense of fullness, feeling of abdominal distention, upper abdominal pain, flatulence (gassiness), eructation (belching), and heartburn.
Short-term treatment of nausea and vomiting of various origins including functional, organic, infectious, diabetic origin, or induced by radiotherapy or medicine therapy. (It is not considered suitable for chronic nausea and vomiting, nor for the routine prophylaxis of postoperative vomiting.)
Treatment of nausea and vomiting induced by dopamine agonists ie, L-dopa and bromocriptine used in Parkinson's disease.
Domperidone may also be given as needed, together with paracetamol for the symptomatic treatment of nausea and vomiting associated with migraine.
Uses of Domperidone in details
Domperidone is used to treat vomiting or nausea caused due to indigestion, diseases or drugs. It is also used to relieve fullness of stomach, belching and heavy bloating, gas and heartburn for a longer period up to 2 weeks.
Domperidone description
Domperidone is a synthetic anticoagulant and an indanedione derivative. It prevents the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver by inhibiting the vitamin K mediated gamma-carboxylation of precursor proteins.
Domperidone dosage
It is recommended to take oral Domperidone before meals. If taken after meals, absorption of the drug is somewhat delayed.
Adults and Adolescents >12 years and weighing ≥35 kg: Tablets: One to two 10-mg tablet 3-4 times/day, with a maximum daily dose of 8 tablets (80 mg).
Oral Suspension:
10-20 mL (of oral susp containing domperidone 1 mg/mL) 3-4 times/day, with a maximum daily dose of 80 mL.Infants and Children: 0.25-0.5 mg/kg 3-4 times/day with a maximum daily dose of 2.4 mg/kg (but do not exceed 80 mg/day).
Tablets are unsuitable for use in children weighing <35 kg.
Oral Suspension:
0.25-0.5 mg/kg 3-4 times/day with a maximum dose of 2.4 mg/kg (not exceeding 80 mL).Domperidone interactions
The concomitant administration of domperidone with phenothiazines, butyrophenones and rauwolfia alkaloids may induce the endocrine disturbances or extrapyramidal disorders. If necessary, monitored carefully and administered cautiously.
Should be administered cautiously in patients receiving digitalis preparations.
The concomitant administration of domperidone with anticholinergic agents may compromise the beneficial effects of domperidone because of depressing the promoting action of gastrointestinal motility.
Theologically, domperidone may have an effect on the absorption of oral preparations, especially slow-releasing or enteric-coated preparations because of increasing gastric motility. But in patients stabilized with digoxin or acetaminophen, the concomitant administration of domperidone had no effect on plasma concentration of these drugs.
It is not reported that domperidone enhances the effect of neuroleptics.
Domperidone inhibits peripheral adverse reactions eg, dyspepsia, nausea, vomiting, induced by dopamine agonist (eg, bromocriptine, levodopa), but has no effect on central nervous system.
As the concomitant administration of domperidone with antacids or acid secretion inhibitors lowers biologic activity of domperidone, these drugs should not be used together.
The actions of domperidone on gastrointestinal function may be antagonised by antimuscarinics and opioid analgesics.
Domperidone side effects
See also:
What are the possible side effects of Domperidone?
Clinical Trial Data: The safety of Domperidone was evaluated in 1221 patients with gastroparesis, dyspepsia, gastro-oesophageal reflux disorder (GERD) or other related conditions in 45 clinical trials included in the safety database. All patients were ≥15 years and received at least 1 dose of oral Domperidone (domperidone base). Slightly fewer than one-half (553/1221) of patients were diabetic. The median total daily dose was 80 mg (range 10-160 mg), with 230 patients receiving a dose >80 mg. Median duration of exposure was 56 days (range 1-2248 days).
Adverse drug reactions (ADRs) reported by ≥1% of patients treated with oral Domperidone in these 45 clinical trials (n=1221) are the following: Psychiatric Disorders: Depression (2.5%), anxiety (1.6%), decreased libido/loss of libido (1.5%).
Nervous System Disorders: Headache (5.6%), somnolence (2.5%), akathisia (1%).
Gastrointestinal Disorders: Diarrhoea (5.2%).
Skin and Subcutaneous Tissue Disorders: Rash (2.8%), pruritus (1.7%).
Reproductive System and Breast Disorders: Breast enlargement/gynaecomastia (5.3%), breast tenderness (4.4%), galactorrhoea (3.3%), amenorrhoea (2.9%), breast pain (2.3%), irregular menstruation (2%), lactation disorder (1.6%).
General Disorders and Administration Site Conditions: Asthenia (1.9%).
ADRs that occurred in <1% of Domperidone-treated patients in the 45 clinical trials (n=1221) are the following: Immune System Disorders: Hypersensitivity (0.2%).
Skin and Subcutaneous Disorders: Urticaria (0.7%).
Reproductive System and Breast Disorders: Breast discharge (0.8%), breast swelling (0.5%).
Dry mouth has been reported with over-the-counter use of Domperidone.
Post-Marketing: In addition to the adverse effects reported during clinical studies and previously mentioned, the following adverse drug reactions provided the frequencies according to the following convention: Very common (≥1/10), common (≥1/100 and <1/10); uncommon (≥1/1000 and <1/100); rare (≥1/10,000 and <1/1000); very rare (<1/10,000, including isolated reports).
The following ADRs are presented by frequency category based on spontaneous reporting rates: Immune System Disorders: Very Rare: Anaphylactic reactions (including anaphylactic shock).
Psychiatric Disorders: Very Rare: Agitation, nervousness.
Nervous System Disorders: Very Rare: Extrapyramidal disorder, convulsion.
Cardiac Disorders: Very Rare: Sudden cardiac death*, serious ventricular arrhythmias*.
Skin and Subcutaneous Tissue Disorders: Very Rare: Angioedema.
Renal and Urinary Disorders: Very Rare: Urinary retention.
Investigations: Very Rare: Abnormal liver function test; increased blood prolactin.
Note: *Based on epidemiology data (as follows).
As the hypophysis is outside the blood-brain barrier, domperidone may cause an increase in prolactin levels. In rare cases, this hyperprolactinaemia may lead to neuro-endocrinological side effects eg, galactorrhoea, gynaecomastia and amenorrhoea.
Extrapyramidal disorder occurs primarily in neonates and infants.
Other central nervous system-related effects of convulsion and agitation are also reported primarily in infants and children.
An increase in the risk of serious ventricular arrhythmias and sudden cardiac death has been reported in some epidemiology studies. Due to the limitations of these data, risk factors and the exact frequency of these adverse reactions could not be defined.
Domperidone contraindications
Hypersensitivity to domperidone or any ingredient of Domperidone.
If patients are taking oral ketoconazole, fluconazole, voriconazole, erythromycin, clarithromycin, telithromycin, amiodarone, selective serotonin reuptake inhibitors, HIV protease inhibitors, calcium antagonists which can increase plasma concentrations of domperidone, leading to a prolonged QTc interval. These medicines can increase plasma concentrations of domperidone leading to a prolonged QTc interval. Patients with long QT syndrome develop a very fast heart rhythm disturbance leading to a sudden loss of consciousness.
Gastrointestinal hemorrhage (bleeding), obstruction, perforation or conditions where gastrointestinal stimulation or movements may be dangerous.
Prolactin-releasing pituitary tumor (prolactinoma).
What is Naproxen?
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID). Naproxen works by reducing hormones that cause inflammation and pain in the body.
Naproxen is used to treat pain or inflammation caused by conditions such as arthritis, ankylosing spondylitis, tendinitis, bursitis, gout, or menstrual cramps.
The delayed-release or extended-release tablets are slower-acting forms of naproxen that are used only for treating chronic conditions such as arthritis or ankylosing spondylitis. These forms of naproxen will not work fast enough to treat acute pain.
Naproxen may also be used for purposes not listed in this medication guide.
Naproxen indications
Carefully consider the potential benefits and risks of Naproxen, Naproxen, ANAPROX, ANAPROX DS or Naproxen Suspension and other treatment options before deciding to use Naproxen, Naproxen, ANAPROX, ANAPROX DS or Naproxen Suspension. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.
Naproxen as Naproxen, Naproxen, ANAPROX, ANAPROX DS or Naproxen Suspension is indicated:
- For the relief of the signs and symptoms of rheumatoid arthritis
- For the relief of the signs and symptoms of osteoarthritis
- For the relief of the signs and symptoms of ankylosing spondylitis
- For the relief of the signs and symptoms of juvenile arthritis
Naproxen as Naproxen Suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient's weight.
Naproxen as Naproxen and Naproxen Suspension is also indicated:
- For relief of the signs and symptoms of tendonitis
- For relief of the signs and symptoms of bursitis
- For relief of the signs and symptoms of acute gout
- For the management of pain
- For the management of primary dysmenorrhea
Naproxen is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products.
How should I use Naproxen?
Use Naproxen as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Naproxen comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Naproxen refilled.
- Swallow Naproxen whole. Do not break, crush, or chew before swallowing.
- Take Naproxen by mouth. It may be taken with food if it upsets your stomach. Taking it with food may not lower the risk of stomach or bowel problems (eg, bleeding, ulcers). Talk with your doctor or pharmacist if you have persistent stomach upset.
- Take Naproxen with a full glass of water (8 oz [240 mL]) as directed by your doctor.
- If you take antacids, cholestyramine, or sucralfate, ask your doctor or pharmacist how to take them with Naproxen.
- If you miss a dose of Naproxen and you are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose. Go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Naproxen.
Uses of Naproxen in details
Naproxen is used to relieve mild to moderate pain from various conditions. It also reduces pain, swelling, and joint stiffness from arthritis. This medication is known as a nonsteroidal anti-inflammatory drug (NSAID). It works by blocking your body's production of certain natural substances that cause inflammation.
If you are treating a chronic condition such as arthritis, ask your doctor about non-drug treatments and/or using other medications to treat your pain. See also Warning section.
This form of naproxen is absorbed slowly and should not be used for pain that needs quick relief (such as during a gout attack). Ask your doctor or pharmacist about using a different form of this drug or other medications for quick relief of pain.
How to use Naproxen
Read the Medication Guide provided by your pharmacist before you start using naproxen and each time you get a refill. If you have any questions, ask your doctor or pharmacist.
Take this medication by mouth as directed by your doctor, usually twice daily with or without food. Swallow this medication whole. Do not break, crush, or chew the tablets. Doing so can release the drug too quickly, increasing the risk of side effects. Take this medication with a full glass of water (8 ounces/240 milliliters) unless your doctor directs you otherwise. Do not lie down for at least 10 minutes after taking this drug.
The dosage is based on your medical condition and response to treatment. To reduce your risk of stomach bleeding and other side effects, take this medication at the lowest effective dose for the shortest possible time. Do not increase your dose or take this drug more often than directed. For ongoing conditions such as arthritis, continue taking this medication as directed by your doctor.
For certain conditions (such as arthritis), it may take up to two weeks of taking this drug regularly until you get the full benefit.
Tell your doctor if your condition does not improve or if it worsens.
Naproxen description
Each tablet contains naproxen 200 mg and sodium 20 mg. It also contains the following inactive ingredients: Povidone, microcrystalline cellulose, talc, magnesium stearate, purified water and Opadry (blue) in the coating. It is lactose- and gluten-free.
The sodium content of Naproxen is low, similar to a slice of wheat bread.
Naproxen dosage
Usual Adult Dose for Ankylosing Spondylitis:
Initial: 250 mg to 500 mg (naproxen) or 275 mg to 550 mg (naproxen sodium) orally twice a day. The initial dose for naproxen sodium controlled-release is two 375 mg tablets (750 mg) orally once a day, one 750 mg tablet orally once a day, or two 500 mg tablets (1000 mg) orally once a day.
Maintenance: May be increased to a daily maximum of 1500 mg (naproxen) or 1650 mg (naproxen sodium) in 2 divided doses, for limited periods up to 6 months. In patients who tolerate lower doses well, the dose of naproxen sodium controlled-release may be increased to two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) orally once a day for limited periods.
Usual Adult Dose for Osteoarthritis:
Initial: 250 mg to 500 mg (naproxen) or 275 mg to 550 mg (naproxen sodium) orally twice a day. The initial dose for naproxen sodium controlled-release is two 375 mg tablets (750 mg) orally once a day, one 750 mg tablet orally once a day, or two 500 mg tablets (1000 mg) orally once a day.
Maintenance: May be increased to a daily maximum of 1500 mg (naproxen) or 1650 mg (naproxen sodium) in 2 divided doses, for limited periods up to 6 months. In patients who tolerate lower doses well, the dose of naproxen sodium controlled-release may be increased to two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) orally once a day for limited periods.
Usual Adult Dose for Rheumatoid Arthritis:
Initial: 250 mg to 500 mg (naproxen) or 275 mg to 550 mg (naproxen sodium) orally twice a day. The initial dose for naproxen sodium controlled-release is two 375 mg tablets (750 mg) orally once a day, one 750 mg tablet orally once a day, or two 500 mg tablets (1000 mg) orally once a day.
Maintenance: May be increased to a daily maximum of 1500 mg (naproxen) or 1650 mg (naproxen sodium) in 2 divided doses, for limited periods up to 6 months. In patients who tolerate lower doses well, the dose of naproxen sodium controlled-release may be increased to two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) orally once a day for limited periods.
Usual Adult Dose for Acute Gout:
750 mg (naproxen) or 825 mg (naproxen sodium) orally one time, followed by 250 mg (naproxen) or 275 mg (naproxen sodium) every 8 hours until the gouty attack has resolved, usually 2 to 3 days. The recommended dose of naproxen sodium controlled-release is two to three 500 mg tablets (1000 to 1500 mg) orally on the first day, followed by two 500 mg tablets (1000 mg) orally daily until the attack has subsided.
Usual Adult Dose for Bursitis:
550 mg naproxen sodium orally once, followed by 550 mg naproxen sodium every 12 hours, or 275 mg (naproxen sodium)/250 mg (naproxen) every 6 to 8 hours as needed. Titrate to a maximum daily dose of 1100 mg naproxen sodium or 1000 mg naproxen. The recommended initial dose of naproxen sodium controlled-release is two 500 mg tablets (1000 mg) orally once a day. For patients requiring greater analgesic benefit, two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) may be used for a limited period. Thereafter, the total daily dose should not exceed two 500 mg tablets (1000 mg).
Usual Adult Dose for Tendonitis:
550 mg naproxen sodium orally once, followed by 550 mg naproxen sodium every 12 hours, or 275 mg (naproxen sodium)/250 mg (naproxen) every 6 to 8 hours as needed. Titrate to a maximum daily dose of 1100 mg naproxen sodium or 1000 mg naproxen. The recommended initial dose of naproxen sodium controlled-release is two 500 mg tablets (1000 mg) orally once a day. For patients requiring greater analgesic benefit, two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) may be used for a limited period. Thereafter, the total daily dose should not exceed two 500 mg tablets (1000 mg).
Usual Adult Dose for Dysmenorrhea:
550 mg naproxen sodium orally once, followed by 550 mg naproxen sodium every 12 hours, or 275 mg (naproxen sodium)/250 mg (naproxen) every 6 to 8 hours as needed. Titrate to a maximum daily dose of 1100 mg naproxen sodium or 1000 mg naproxen.
Over-the-counter preparation: naproxen sodium 220 mg orally every 8 hours as needed. Do not exceed 2 caplets in any 8- to 12-hour period.
The recommended initial dose of naproxen sodium controlled-release is two 500 mg tablets (1000 mg) orally once a day. For patients requiring greater analgesic benefit, two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) may be used for a limited period. Thereafter, the total daily dose should not exceed two 500 mg tablets (1000 mg).
Usual Adult Dose for Pain:
550 mg naproxen sodium orally once, followed by 550 mg naproxen sodium every 12 hours, or 275 mg (naproxen sodium)/250 mg (naproxen) every 6 to 8 hours as needed. Titrate to a maximum daily dose of 1100 mg naproxen sodium or 1000 mg naproxen.
Over-the-counter preparation: naproxen sodium 220 mg orally every 8 hours as needed. Do not exceed 2 caplets in any 8- to 12-hour period.
The recommended initial dose of naproxen sodium controlled-release is two 500 mg tablets (1000 mg) orally once a day. For patients requiring greater analgesic benefit, two 750 mg tablets (1500 mg) or three 500 mg tablets (1500 mg) may be used for a limited period. Thereafter, the total daily dose should not exceed two 500 mg tablets (1000 mg).
Usual Geriatric Dose for Pain:
Over-the-counter preparation - 220 mg (naproxen sodium) orally every 12 hours or 250 mg (naproxen) orally every 8 hours as needed.
Usual Pediatric Dose for Fever:
Dosage guidelines are based on naproxen:
Greater than 2 years: 2.5 to 10 mg/kg/dose. Maximum daily dose is 10 mg/kg, given every 8 to 12 hours.
Usual Pediatric Dose for Pain:
Dosage guidelines are based on naproxen:
Greater than 2 years: 2.5 to 10 mg/kg/dose. Maximum daily dose is 10 mg/kg, given every 8 to 12 hours.
Usual Pediatric Dose for Juvenile Rheumatoid Arthritis:
Dosage guidelines are based on naproxen:
Greater than or equal to 2 years: 5 mg/kg orally twice a day. Maximum dose: 1000 mg/day.
Naproxen interactions
See also:
What other drugs will affect Naproxen?
The use of NSAIDs in patients who are receiving ACE inhibitors may potentiate renal disease states.
In vitro studies have shown that naproxen anion, because of its affinity for protein, may displace from their binding sites other drugs which are also albumin-bound.
Theoretically, the naproxen anion itself could likewise be displaced. Short-term controlled studies failed to show that taking the drug significantly affects prothrombin times when administered to individuals on coumarin-type anticoagulants. Caution is advised nonetheless, since interactions have been seen with other nonsteroidal agents of this class. Similarly, patients receiving the drug and a hydantoin, sulfonamide or sulfonylurea should be observed for signs of toxicity to these drugs.
Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.
The natriuretic effect of furosemide has been reported to be inhibited by some drugs of this class. Inhibition of renal lithium clearance leading to increases in plasma lithium concentrations has also been reported. Naproxen and other NSAIDs can reduce the antihypertensive effect of propranolol and other beta-blockers.
Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.
Caution should be used if naproxen is administered concomitantly with methotrexate. Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.
Drug/Laboratory Test Interactions
Naproxen may decrease platelet aggregation and prolong bleeding time. This effect should be kept in mind when bleeding times are determined. The administration of naproxen may result in increased urinary values for 17-ketogenic steroids because of an interaction between the drug and/or its metabolites with m-dinitrobenzene used in this assay. Although 17-hydroxy-corticosteroid measurements (Porter-Silber test) do not appear to be artifactually altered, it is suggested that therapy with naproxen be temporarily discontinued 72 hours before adrenal function tests are performed if the Porter-Silber test is to be used.
Naproxen may interfere with some urinary assays of 5-hydroxy indoleacetic acid (5HIAA).
Naproxen side effects
See also:
What are the possible side effects of Naproxen?
Adverse reactions reported in controlled clinical trials in 960 patients treated for rheumatoid arthritis or osteoarthritis are listed below. In general, reactions in patients treated chronically were reported 2 to 10 times more frequently than they were in short-term studies in the 962 patients treated for mild to moderate pain or for dysmenorrhea. The most frequent complaints reported related to the gastrointestinal tract.
A clinical study found gastrointestinal reactions to be more frequent and more severe in rheumatoid arthritis patients taking daily doses of 1500 mg Naproxen compared to those taking 750 mg Naproxen.
In controlled clinical trials with about 80 pediatric patients and in well-monitored, open-label studies with about 400 pediatric patients with juvenile arthritis treated with Naproxen, the incidence of rash and prolonged bleeding times were increased, the incidence of gastrointestinal and central nervous system reactions were about the same, and the incidence of other reactions were lower in pediatric patients than in adults.
In patients taking Naproxen in clinical trials, the most frequently reported adverse experiences in approximately 1% to 10% of patients are:
Gastrointestinal (GI) Experiences, including: heartburn*, abdominal pain*, nausea*, constipation*, diarrhea, dyspepsia, stomatitis
Central Nervous System: headache*, dizziness*, drowsiness*, lightheadedness, vertigo
Dermatologic: pruritus (itching)*, skin eruptions*, ecchymoses*, sweating, purpura
Special Senses: tinnitus*, visual disturbances, hearing disturbances
Cardiovascular: edema*, palpitations
General: dyspnea*, thirst
*Incidence of reported reaction between 3% and 9%. Those reactions occurring in less than 3% of the patients are unmarked.
In patients taking NSAIDs, the following adverse experiences have also been reported in approximately 1% to 10% of patients.
Gastrointestinal (GI) Experiences, including: flatulence, gross bleeding/perforation, GI ulcers (gastric/duodenal), vomiting
General: abnormal renal function, anemia, elevated liver enzymes, increased bleeding time, rashes
The following are additional adverse experiences reported in <1% of patients taking Naproxen during clinical trials and through postmarketing reports. Those adverse reactions observed through postmarketing reports are italicized.
Body as a Whole: anaphylactoid reactions, angioneurotic edema, menstrual disorders, pyrexia (chills and fever)
Cardiovascular: congestive heart failure, vasculitis, hypertension, pulmonary edema
Gastrointestinal: inflammation, bleeding (sometimes fatal, particularly in the elderly), ulceration, perforation and obstruction of the upper and lower gatrointestinal tract. Esophagitis, stomatitis, hematemesis, pancreatitis, vomiting, colitis, exacerbation of inflammatory bowel disease (ulcerative colitis, Crohn’s disease)
Hepatobiliary: jaundice, abnormal liver function tests, hepatitis (some causes have been fatal)
Hemic and Lymphatic: eosinophilia, leucopenia, melena, thrombocytopenia, agranulocytosis, granulocytopenia, hemolytic anemia, aplastic anemia
Metabolic and Nutritional: hyperglycemia, hypoglycemia
Nervous System: inability to concentrate, depression, dream abnormalities, insomnia, malaise, myalgia, muscle weakness, aseptic meningitis, cognitive dysfunction, convulsions
Respiratory: eosinophilic pneumonitis, asthma
Dermatologic: alopecia, urticaria, skin rashes, toxic epidermal necrolysis, erythema multiforme, erythema nodosum, fixed drug eruption, lichen planus, pustular reaction, systemic lupus erythematoses, Stevens-Johnson syndrome, photosensitive dermatitis, photosensitivity reactions, including rare cases resembling porphyria cutanea tarda (pseudoporphyria) or epidermolysis bullosa. If skin fragility, blistering or other symptoms suggestive of pseudoporphyria occur, treatment should be discontinued and the patient monitored.
Special Senses: hearing impairment, corneal opacity, papillitis, retrobulbar optic neuritis, papilledema
Urogenital: glomerular nephritis, hematuria, hyperkalemia, interstitial nephritis, nephrotic syndrome, renal disease, renal failure, renal papillary necrosis, raised serum creatinine
Reproduction (Female): infertility
In patients taking NSAIDs, the following adverse experiences have also been reported in <1% of patients.
Body as a Whole: fever, infection, sepsis, anaphylactic reactions, appetite changes, death
Cardiovascular: hypertension, tachycardia, syncope, arrhythmia, hypotension, myocardial infarction
Gastrointestinal: dry mouth, esophagitis, gastric/peptic ulcers, gastritis, glossitis, eructation
Hepatobiliary: hepatitis, liver failure
Hemic and Lymphatic: rectal bleeding, lymphadenopathy, pancytopenia
Metabolic and Nutritional: weight changes
Nervous System: anxiety, asthenia, confusion, nervousness, paresthesia, somnolence, tremors, convulsions, coma, hallucinations
Respiratory: asthma, respiratory depression, pneumonia
Dermatologic: exfoliative dermatitis
Special Senses: blurred vision, conjunctivitis
Urogenital: cystitis, dysuria, oliguria/polyuria, proteinuri
Naproxen contraindications
See also:
What is the most important information I should know about Naproxen?
Naproxen, Naproxen, ANAPROX, ANAPROX DS and Naproxen Suspension are contraindicated in patients with known hypersensitivity to naproxen and naproxen sodium.
Naproxen, Naproxen, ANAPROX, ANAPROX DS and Naproxen Suspension should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients.
Naproxen, Naproxen, ANAPROX, ANAPROX DS and Naproxen Suspension are contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
Active ingredient matches for Domperidone/naproxen:
Domperidone/naproxen
List of Domperidone/naproxen substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| MINADO | |
| MINADO 500 MG/10 MG TABLET 1 strip / 10 tablets each (Tas Med India Pvt Ltd) | $ 0.63 |
| MINADO TABLET 1 strip / 10 tablets each (Tas Med India Pvt Ltd) | $ 0.46 |
| Minado Tablet (Tas Med India Pvt Ltd) | $ 0.05 |
| NAPRA-D (India) | |
| 10's (Intas) | |
| Napra-D Naproxen 250 mg, domperidone10 mg. FC-TAB / 10 (Intas) | |
| Napra-D Naproxen 500 mg, domperidone10 mg. FC-TAB / 10 (Intas) | |
| NAPRA-D 250MG TABLET 1 strip / 10 tablets each (Intas) | $ 0.55 |
| NAPRA-D 500MG TABLET 1 strip / 10 tablets each (Intas) | $ 0.76 |
| NAPRA-D film-coated tab 10's (Intas) | $ 0.59 |
| Napra-D Naproxen 250 mg, domperidone10 mg. FC-TAB / 10 (Intas) | |
| Napra-D Naproxen 500 mg, domperidone10 mg. FC-TAB / 10 (Intas) | |
| NAPRODOM (India) | |
| 10's (Crescent Formulations Pvt Ltd (Crescent Therapeutics Ltd. )) | $ 0.63 |
| Naprodom 250+10 Tablet (Crescent Formulations Pvt Ltd (Crescent Therapeutics Ltd. )) | $ 0.05 |
| Naprodom 500+10 Tablet (Crescent Formulations Pvt Ltd (Crescent Therapeutics Ltd. )) | $ 0.06 |
| Naprodom Naproxen 250 mg, domperidone10 mg. TAB / 10 (Crescent Formulations Pvt Ltd (Crescent Therapeutics Ltd. )) | $ 0.46 |
| Naprodom Naproxen 500 mg, domperidone10 mg. TAB / 10 (Crescent Formulations Pvt Ltd (Crescent Therapeutics Ltd. )) | $ 0.63 |
| NAPRODOM 250MG TABLET 1 strip / 10 tablets each (Crescent Formulations Pvt Ltd (Crescent Therapeutics Ltd. )) | $ 0.49 |
| NAPRODOM 500MG TABLET 1 strip / 10 tablets each (Crescent Formulations Pvt Ltd (Crescent Therapeutics Ltd. )) | $ 0.70 |
| NAPRODOM tab 10's (Crescent Formulations Pvt Ltd (Crescent Therapeutics Ltd. )) | $ 0.63 |
| Naprodom Naproxen 250 mg, domperidone10 mg. TAB / 10 (Crescent Formulations Pvt Ltd (Crescent Therapeutics Ltd. )) | $ 0.46 |
| Naprodom Naproxen 500 mg, domperidone10 mg. TAB / 10 (Crescent Formulations Pvt Ltd (Crescent Therapeutics Ltd. )) | $ 0.63 |
| Naprodom 250mg Tablet (Crescent Formulations Pvt Ltd (Crescent Therapeutics Ltd. )) | $ 0.05 |
| Naprodom 500mg Tablet (Crescent Formulations Pvt Ltd (Crescent Therapeutics Ltd. )) | $ 0.07 |
| Naxdom (India) | |
| 10's (Sun Pharmaceutical Industries Ltd.) | $ 0.59 |
| Naxdom Domperidone 10 mg, Naproxensodium 250 mg FC-TAB / 10 (Sun Pharmaceutical Industries Ltd.) | $ 0.43 |
| Naxdom Domperidone 10 mg, Naproxensodium 500 mg. FC-TAB / 10 (Sun Pharmaceutical Industries Ltd.) | $ 0.59 |
| Naxdom 500+10 Tablet (Sun Pharmaceutical Industries Ltd.) | $ 0.06 |
| Naxdom 250+10 Tablet (Sun Pharmaceutical Industries Ltd.) | $ 0.04 |
| NAXDOM 250MG TABLET 1 strip / 10 tablets each (Sun Pharmaceutical Industries Ltd.) | $ 0.57 |
| NAXDOM 500 MG/10 MG TABLET 1 strip / 10 tablets each (Sun Pharmaceutical Industries Ltd.) | $ 0.75 |
| NAXDOM film-coated tab 10's (Sun Pharmaceutical Industries Ltd.) | $ 0.59 |
| Naxdom 250 Tablet (Sun Pharmaceutical Industries Ltd.) | $ 0.06 |
| PANDEX | |
| PANDEX 500MG/10MG TABLET 1 strip / 10 tablets each (Mission Research Laboratories Pvt Ltd) | $ 0.86 |
| Pandex Tablet (Mission Research Laboratories Pvt Ltd) | $ 0.09 |
| Xenadom (India) | |
| Xenadom Naproxen 250 mg, domperidone10 mg. TAB / 10 (Mesmer (Icon)) | $ 0.59 |
| Xenadom Naproxen 500 mg, domperidone10 mg. TAB / 10 (Mesmer (Icon)) | $ 0.78 |
| XENADOM 10 MG/500 MG TABLET 1 strip / 10 tablets each (Mesmer (Icon)) | $ 0.89 |
| XENADOM 250 MG/10 MG TABLET 1 strip / 10 tablets each (Mesmer (Icon)) | $ 0.76 |
| XENADOM tab 10's (Mesmer (Icon)) | $ 0.78 |
| Xenadom 10 mg/500 mg Tablet (Mesmer (Icon)) | $ 0.09 |
| Xenadom 250 mg/10 mg Tablet (Mesmer (Icon)) | $ 0.08 |
See 41 substitutes for Domperidone/naproxen | |
References
- DailyMed. "NAPROXEN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "domperidone". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- PubChem. "NAPROXEN". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Domperidone/naproxen are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Domperidone/naproxen. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
